← Back to Screener
Prelude Therapeutics Incorporated (PRLD)
Price$4.51
Favorite Metrics
Price vs S&P 500 (26W)243.63%
Price vs S&P 500 (4W)39.00%
Market Capitalization$279.73M
All Metrics
Book Value / Share (Quarterly)$1.09
P/TBV (Annual)0.93x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.90
Price vs S&P 500 (YTD)48.97%
Net Profit Margin (TTM)-298.04%
EPS (TTM)$-0.47
10-Day Avg Trading Volume0.45M
EPS Excl Extra (TTM)$-0.47
EPS (Annual)$-1.29
ROI (Annual)-144.96%
Cash / Share (Quarterly)$1.64
Revenue Growth QoQ (YoY)41.00%
ROA (Last FY)-70.41%
EBITD / Share (TTM)$-0.45
ROE (5Y Avg)-78.25%
Operating Margin (TTM)-311.09%
Cash Flow / Share (Annual)$-0.90
P/B Ratio4.08x
P/B Ratio (Quarterly)2.39x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)20.14x
ROA (TTM)-30.65%
EPS Incl Extra (Annual)$-1.29
Current Ratio (Annual)1.99x
Quick Ratio (Quarterly)1.95x
3-Month Avg Trading Volume0.39M
52-Week Price Return476.62%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.35
P/S Ratio (Annual)23.04x
Asset Turnover (Annual)0.09x
52-Week High$5.54
EPS Excl Extra (Annual)$-1.29
CapEx CAGR (5Y)-35.92%
26-Week Price Return252.38%
Quick Ratio (Annual)1.95x
13-Week Price Return96.46%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.99x
Enterprise Value$244.474
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)-25.83%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-819.59%
Cash / Share (Annual)$1.64
3-Month Return Std Dev138.66%
Net Income / Employee (TTM)$-0
ROE (Last FY)-144.96%
EPS Basic Excl Extra (Annual)$-1.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.47
ROI (TTM)-56.90%
P/S Ratio (TTM)23.04x
Revenue / Share (Annual)$0.16
Tangible BV / Share (Annual)$4.08
Price vs S&P 500 (52W)441.53%
Year-to-Date Return53.10%
5-Day Price Return1.60%
EPS Normalized (Annual)$-1.29
ROA (5Y Avg)-55.14%
Net Profit Margin (Annual)-819.59%
Month-to-Date Return29.82%
Cash Flow / Share (TTM)$-2.12
EBITD / Share (Annual)$-1.27
Operating Margin (Annual)-861.33%
ROI (5Y Avg)-78.22%
EPS Basic Excl Extra (TTM)$-0.47
P/TBV (Quarterly)0.77x
P/B Ratio (Annual)2.39x
Pretax Margin (TTM)-298.04%
Book Value / Share (Annual)$1.09
Price vs S&P 500 (13W)93.59%
Beta0.91x
Revenue / Share (TTM)$0.15
ROE (TTM)-56.90%
52-Week Low$0.72
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRLDPrelude Therapeutics Incorporated | 23.04x | — | — | — | $4.51 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Prelude Therapeutics is a clinical-stage precision oncology company developing small molecule therapies targeting key cancer driver mechanisms in high unmet need indications. The company's pipeline includes four candidates in clinical development: PRT1419 (MCL1 inhibitor), PRT2527 (CDK9 inhibitor), PRT3645 (next-generation CDK4/6 inhibitor), and PRT3789 (first-in-class SMARCA2/BRM protein degrader).